Actively Recruiting
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Led by Jon Simmons · Updated on 2021-05-28
44
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
J
Jon Simmons
Lead Sponsor
U
University of South Alabama
Collaborating Sponsor
AI-Summary
What this Trial Is About
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
CONDITIONS
Official Title
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female age 18 or older
- Receiving high flow oxygen at 6 liters per minute or more, or on mechanical ventilation
- Clinical diagnosis of COVID-19 with positive PCR test
- Clinical diagnosis of COVID-19 with negative PCR test but symptoms and characteristic chest CT lesions
You will not qualify if you...
- Known allergy to Pulmozyme
- Under 18 years of age
- Grave condition with expected death within 48 hours as judged by physician
- Currently enrolled in another clinical trial receiving investigational drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of South Alabama
Mobile, Alabama, United States, 36617
Actively Recruiting
Research Team
J
Jon D Simmons, M.D.
CONTACT
W
Wendy Blount, RN, MSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here